Advertisement

Topics

New test may turn AZ's Lynparza into precision drug for prostate cancer

15:12 EDT 18 Jun 2017 | Reuters

LONDON (Reuters) - Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

Original Article: New test may turn AZ's Lynparza into precision drug for prostate cancer

NEXT ARTICLE

More From BioPortfolio on "New test may turn AZ's Lynparza into precision drug for prostate cancer"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...